A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ
NCT00189254
·
clinicaltrials.gov ↗
COMPLETED
Status
72
Enrollment
INDUSTRY
Sponsor class
Conditions
Actinic Keratoses
Interventions
DRUG:
Imiquimod
Sponsor
MEDA Pharma GmbH & Co. KG